VEGFA and hemorrhagic stroke: In a rodent model of ischemic stroke, they demonstrated that delivery of recombinant VEGFA, 48 hours after infarct, increased revascularization and improved neurologic outcome, whereas administration of VEGFA in the acute setting increased blood-brain-barrier leak and elevated the risk of transformation to hemorrhagic stroke.